Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC.ASMB · Entity 5216 | Director | June 04, 2026 | June 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ASSEMBLY BIOSCIENCES, INC.
Report date June 04, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.11 · Expires 2036-06-04 | Direct | 8,000 |
Reported balance
After 2026-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 8,000 · Balance 8,000 F1: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 4, 2027 and (2) the date of the Issuer's 2027 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 4, 2027 and (2) the date of the Issuer's 2027 annual meeting of stockholders.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
TearLab Corp
Report date July 09, 2020 · Filed July 09, 2020
Section 16 reporting ended · disclosed 2020-07-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-07-09 transaction · row 1
1 source rowRow 1 · 2020-07-09 · Other · Disposed 8,833 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated May 11, 2020 (the "Merger Agreement"), among Accelmed Partners II LP, a Cayman Islands exempted limited partnership ("Buyer"), the Issuer and Accelmed Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Buyer, each issued and outstanding share of Issuer common stock and preferred stock (other than Cancelled Shares (as defined in the Merger Agreement)) was cancelled and automatically converted into the right to receive an amount equal to $0.0586 per share in cash, without interest and less any required withholding taxes, effective at the time of the Merger (as defined in the Merger Agreement). |
| Warrant (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $11.25 · Expires 2021-05-09 | Direct | 0 |
Reported balance
After 2020-07-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-07-09 · Other · Disposed 1,666 · Balance 0 F3: Pursuant to the terms of the Warrant Termination Agreement by and between the Reporting Person and the Issuer, effective July 2, 2020, immediately prior to the consummation of Merger, the warrant automatically terminated and the Reporting Person is entitled to receive a total payment of $60.81 in exchange for such cancellation, to be paid within five (5) days following the consummation of the Merger. F2: The warrant will be exercisable from the later of (i) stockholder approval to increase the authorized number of shares of common stock of the Issuer, and (ii) 12 months from the date of issuance and will expire five years from the date on which such warrant becomes exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger, dated May 11, 2020 (the "Merger Agreement"), among Accelmed Partners II LP, a Cayman Islands exempted limited partnership ("Buyer"), the Issuer and Accelmed Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Buyer, each issued and outstanding share of Issuer common stock and preferred stock (other than Cancelled Shares (as defined in the Merger Agreement)) was cancelled and automatically converted into the right to receive an amount equal to $0.0586 per share in cash, without interest and less any required withholding taxes, effective at the time of the Merger (as defined in the Merger Agreement).
F2: The warrant will be exercisable from the later of (i) stockholder approval to increase the authorized number of shares of common stock of the Issuer, and (ii) 12 months from the date of issuance and will expire five years from the date on which such warrant becomes exercisable.
F3: Pursuant to the terms of the Warrant Termination Agreement by and between the Reporting Person and the Issuer, effective July 2, 2020, immediately prior to the consummation of Merger, the warrant automatically terminated and the Reporting Person is entitled to receive a total payment of $60.81 in exchange for such cancellation, to be paid within five (5) days following the consummation of the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2026 Filed Jun 5, 2026 20:30 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $24.11 | $0.00 |
DisclosureSEC source: 0001193125-26-259697 · ownership.xml · derivative · entry 1 ALTIG ANTHONY E · CIK 0001215907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2036-06-04 F1 · derivative.exercise_date: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 4, 2027 and (2) the date of the Issuer's 2027 annual meeting of stockholders. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:05 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $15.81 | $0.00 |
DisclosureSEC source: 0000950170-25-083694 · ownership.xml · derivative · entry 1 ALTIG ANTHONY E · CIK 0001215907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,500 Underlying: Common Stock · 3,500 shares Expires 2035-06-05 F1 · derivative.exercise_date: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 5, 2026 and (2) the date of the Issuer's 2026 annual meeting of stockholders. Read SEC document |
| May 29, 2024 Filed May 30, 2024 20:05 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 2,750 | $0.00 Strike: $15.06 | $0.00 |
DisclosureSEC source: 0000950170-24-066562 · ownership.xml · derivative · entry 1 ALTIG ANTHONY E · CIK 0001215907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,750 Underlying: Common Stock · 2,750 shares Expires 2034-05-29 F1 · derivative.exercise_date: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) May 29, 2025 and (2) the date of the Issuer's 2025 annual meeting of stockholders. Read SEC document |
| May 25, 2023 Filed May 30, 2023 20:10 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.97 | $0.00 |
DisclosureSEC source: 0001209191-23-032862 · doc4.xml · derivative · entry 1 ALTIG ANTHONY E · CIK 0001215907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-05-25 F1 · derivative.exercise_date: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) May 25, 2024 and (2) the date of the Issuer's 2024 annual meeting of stockholders. Read SEC document |
| May 25, 2022 Filed May 27, 2022 20:25 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.69 | $0.00 |
DisclosureSEC source: 0001209191-22-032544 · doc4.xml · derivative · entry 1 ALTIG ANTHONY E · CIK 0001215907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-05-25 F1 · derivative.exercise_date: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) May 25, 2023 and (2) the date of the Issuer's 2023 annual meeting of stockholders. Read SEC document |
| May 20, 2021 Filed May 24, 2021 20:54 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $4.03 | $0.00 |
DisclosureSEC source: 0001209191-21-035366 · doc4.xml · derivative · entry 1 ALTIG ANTHONY E · CIK 0001215907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-05-20 F1 · derivative.exercise_date: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) May 20, 2022 and (2) the date of the Issuer's 2022 annual meeting of stockholders. Read SEC document |
| July 09, 2020 Filed Jul 9, 2020 16:03 UTC | TearLab Corp TEAR · Entity 147894 | OtherWarrant (right to purchase) · Derivative | 1,666 | $60.81 Strike: $11.25 | $101,309.46 |
DisclosureSEC source: 0001493152-20-012956 · ownership.xml · derivative · entry 2 ALTIG ANTHONY E · CIK 0001215907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,666 shares Expires 2021-05-09 F3 · price: Pursuant to the terms of the Warrant Termination Agreement by and between the Reporting Person and the Issuer, effective July 2, 2020, immediately prior to the consummation of Merger, the warrant automatically terminated and the Reporting Person is entitled to receive a total payment of $60.81 in exchange for such cancellation, to be paid within five (5) days following the consummation of the Merger. F2 · derivative.exercise_date: The warrant will be exercisable from the later of (i) stockholder approval to increase the authorized number of shares of common stock of the Issuer, and (ii) 12 months from the date of issuance and will expire five years from the date on which such warrant becomes exercisable. Read SEC document |
| July 09, 2020 Filed Jul 9, 2020 16:03 UTC | TearLab Corp TEAR · Entity 147894 | OtherCommon Stock | 8,833 | $0.06 | $517.61 |
DisclosureSEC source: 0001493152-20-012956 · ownership.xml · nonDerivative · entry 1 ALTIG ANTHONY E · CIK 0001215907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated May 11, 2020 (the "Merger Agreement"), among Accelmed Partners II LP, a Cayman Islands exempted limited partnership ("Buyer"), the Issuer and Accelmed Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Buyer, each issued and outstanding share of Issuer common stock and preferred stock (other than Cancelled Shares (as defined in the Merger Agreement)) was cancelled and automatically converted into the right to receive an amount equal to $0.0586 per share in cash, without interest and less any required withholding taxes, effective at the time of the Merger (as defined in the Merger Agreement). Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 20:38 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $20.47 | $0.00 |
DisclosureSEC source: 0001209191-20-036627 · doc4.xml · derivative · entry 1 ALTIG ANTHONY E · CIK 0001215907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-06-11 F1 · derivative.exercise_date: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 11, 2021 and (2) the date of the Issuer's 2021 annual meeting of stockholders. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 16:34 UTC | TearLab Corp TEAR · Entity 147894 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001493152-20-003823 · ownership.xml · derivative · entry 1 ALTIG ANTHONY E · CIK 0001215907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2030-03-10 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the Option shall be vested and exercisable upon the date of grant. Read SEC document |
| May 17, 2019 Filed May 17, 2019 23:32 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $15.22 | $0.00 |
DisclosureSEC source: 0001144204-19-027155 · tv521915_4.xml · derivative · entry 1 ALTIG ANTHONY E · CIK 0001215907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-05-17 F1 · derivative.exercise_date: The shares of common stock underlying the option will vest upon the earlier of (i) May 17, 2020 and (ii) the date of the Issuer's 2020 annual meeting of stockholders. Read SEC document |
| May 30, 2018 Filed Jun 1, 2018 21:45 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $42.09 | $0.00 |
DisclosureSEC source: 0001144204-18-032465 · tv495552_4.xml · derivative · entry 1 ALTIG ANTHONY E · CIK 0001215907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2028-05-30 F1 · derivative.exercise_date: The shares of common stock underlying the option will vest upon the earlier of (i) May 30, 2019 and (ii) the date of the Issuer's 2019 annual meeting of stockholders. Read SEC document |
| February 07, 2018 Filed Feb 9, 2018 16:17 UTC | TearLab Corp TEAR · Entity 147894 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001437749-18-002163 · rdgdoc.xml · derivative · entry 1 ALTIG ANTHONY E · CIK 0001215907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-02-07 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the Option shall be vested and exercisable upon the date of grant. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 20:32 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $25.96 | $0.00 |
DisclosureSEC source: 0001144204-17-031035 · v468320_4.xml · derivative · entry 1 ALTIG ANTHONY E · CIK 0001215907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2027-06-01 F1 · derivative.exercise_date: The shares of Common Stock underlying the option will vest upon the earlier of (i) June 1, 2018 and (ii) the date of the Issuer's 2018 annual meeting of stockholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.